highperformr logo

Biocytogen's Overview

Total employees174
HeadquartersBeijing
Founded2009

Biocytogen is a global biotechnology company listed on the Hong Kong Stock Exchange (HKEX: 1110.HK) dedicated to discovering, developing, and delivering innovative antibody-based therapeutics. The company leverages its proprietary RenMice® platforms for fully human monoclonal and bispecific antibody discovery, alongside extensive capabilities in gene editing and preclinical animal model development. Biocytogen's integrated approach supports the entire drug discovery pipeline, from target validation to clinical candidate selection, through in-house projects and extensive global partnerships. Their mission is to become a global leader in new drug research and development for the benefit of patients worldwide.

Where is Biocytogen's Headquarters?

HQ Function

Serves as the main operational and R&D center, overseeing global strategy, core research programs including antibody discovery and gene editing, preclinical studies, and corporate administrative functions.

Notable Features:

Features state-of-the-art research laboratories, advanced animal model facilities including large-scale specific pathogen-free (SPF) animal housing, and collaborative workspaces designed to foster cutting-edge scientific discovery.

Work Culture:

A research-driven and innovative environment characterized by scientific rigor, collaboration among multidisciplinary teams, and a strong commitment to accelerating the development of new medicines.

HQ Significance:

Strategically positioned in a major Chinese biotech cluster, providing access to a rich talent pool, academic collaborations, and proximity to the rapidly expanding Asian pharmaceutical market. It underpins Biocytogen's R&D capabilities and global ambitions.

Values Reflected in HQ: The headquarters reflects Biocytogen's core values of innovation, scientific excellence, and a global outlook, evident in its advanced infrastructure and strategic location.

Location:

Biocytogen operates globally with key facilities and offices in China (Beijing, Haimen), the United States (Woburn, MA; Foster City, CA), and Germany (Heidelberg). This international network supports worldwide R&D collaborations, antibody discovery projects, preclinical services, clinical trial management, and business development activities, enabling the company to serve pharmaceutical and biotech partners across Asia, North America, and Europe.

Street Address:

No.12A Life Science Park Road, Changping District

City:

Beijing

State/Province:

Beijing

Country:

China

Biocytogen's Global Presence

Woburn, Massachusetts, USA

Address: 400 TradeCenter Dr., Suite 1680, Woburn, MA 01801, USA

To strengthen Biocytogen's presence in the key US East Coast biotech hub, fostering collaborations and providing localized support for its antibody discovery platforms and preclinical services.

Haimen, Jiangsu, China

Address: Building B16, Biomedical Park, Linjiang New District, Haimen, Jiangsu, 226100, P.R.China

Enhances Biocytogen's capacity for large-scale production of animal models and antibodies, and supports extensive preclinical research services, leveraging regional biomanufacturing and research strengths.

Heidelberg, Germany

Address: Biocytogen GmbH, Technology Park Heidelberg, Im Neuenheimer Feld 582, 69120 Heidelberg, Germany

To establish and grow Biocytogen's footprint in the European biotechnology landscape, driving partnerships and providing tailored services to European clients.

Foster City, California, USA

Address: 950 Tower Lane, Suite 1030, Foster City, CA 94404, USA

To effectively manage and execute clinical trials, particularly in the US, leveraging the proximity to the West Coast biotech cluster and its associated clinical research infrastructure and expertise.

Buying Intent Signals for Biocytogen

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Biocytogen

As of April 2025, Biocytogen' leadership includes:

Yuelei Shen, Ph.D. - Founder, Chairman of the Board, President and CEO
Chun-Min Chang, Ph.D., MBA - Vice Chairman of the Board, Senior Vice President, CEO of Biocytogen Boston
Jie He, MBA - Chief Financial Officer and Joint Company Secretary
Yi Yang, Ph.D. - Senior Vice President, Chief Scientific Officer
Rong Chen, M.D., Ph.D. - Chief Medical Officer
Vivian Tian, M.D., Ph.D., MBA - Senior Vice President, Global Head of Business Development
Ni Li, Ph.D. - Senior Vice President, Head of Preclinical Research Division

Investors of Biocytogen

Biocytogen has been backed by several prominent investors over the years, including:

CMB International Capital Corporation
SDIC Venture Capital
China Life Healthcare Fund
Lake Bleu Capital
OrbiMed
Octagon Capital Advisors
Vivo Capital

Executive New Hires/Exits in the Last 12 Months

Hire1
Exits1

In early 2023, Biocytogen experienced a significant transition in its financial leadership with the appointment of a new Chief Financial Officer. The broader executive team has largely maintained stability since this change, focusing on strategic growth and pipeline advancement.

Departures

Ling Zhang, Ling Zhang resigned as Chief Financial Officer and Executive Director of Biocytogen.

New Appointments:

Jie He, Jie He was appointed as the Chief Financial Officer of Biocytogen, bringing extensive experience in financial management.

Technology (Tech Stack) used by Biocytogen

Discover the tools Biocytogen uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Biocytogen Email Formats and Examples

Biocytogen typically uses a standard professional email format for its employees, most commonly [firstname].[lastname]@biocytogen.com. Variations may exist for general inquiries or specific regional business development contacts (e.g., bd_us@biocytogen.com).

[first].[last]@biocytogen.com

Format

john.smith@biocytogen.com

Example

85%

Success rate

News and media

Biocytogen News RoomMay 14, 2024

Biocytogen Announces Antibody Evaluation and Option Agreement with Ono Pharmaceutical

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced an antibody evaluation and option agreement with Ono Pharmaceutical Co., Ltd. for a jointly selected antibody target. Biocytogen will grant Ono an option to license antibodies generated by Biocytogen for the development, manufacturing and commercialization of antibody drug conjugates (ADCs) and other GPRC5D-targeting drugs globally....more

Biocytogen News RoomApril 29, 2024

Biocytogen Announces its Subsidiary Eucure Biopharma Entered into a Clinical Trial Collaboration and Supply Agreement with Merck for a Phase I Clinical Trial of YH008, a PD-1/IL-2 Bispecific Antibody, in Combination with KEYTRUDA® (pembrolizumab) for Patients with Advanced Solid Tumors

Biocytogen's subsidiary, Eucure Biopharma, has entered into a clinical trial collaboration and supply agreement with Merck (MSD) to evaluate YH008, a PD-1/IL-2 bispecific antibody, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), for patients with advanced solid tumors in Australia....more

Biocytogen News RoomApril 2, 2024

Biocytogen Announces Antibody Evaluation and Option Agreement with Takeda

Biocytogen announced an antibody evaluation and option agreement with Takeda. Under the agreement, Takeda will evaluate certain Biocytogen-proprietary monoclonal antibodies with the potential for therapeutic drug development. Takeda will have the option to license selected antibodies for global development and commercialization....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Biocytogen, are just a search away.